Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long co… Read more
Innovation1 Biotech Inc (IVBT) - Total Assets
Latest total assets as of February 2024: $121.50K USD
Based on the latest financial reports, Innovation1 Biotech Inc (IVBT) holds total assets worth $121.50K USD as of February 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Innovation1 Biotech Inc - Total Assets Trend (2018–2023)
This chart illustrates how Innovation1 Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Innovation1 Biotech Inc - Asset Composition Analysis
Current Asset Composition (August 2023)
Innovation1 Biotech Inc's total assets of $121.50K consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.68K | 2.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Innovation1 Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innovation1 Biotech Inc's current assets represent 95.7% of total assets in 2023, a decrease from 99.5% in 2018.
- Cash Position: Cash and equivalents constituted 65.6% of total assets in 2023, down from 89.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 2.2% of total assets.
Innovation1 Biotech Inc Competitors by Total Assets
Key competitors of Innovation1 Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
464680
KQ:464680
|
Korea | ₩31.23 Billion |
|
Cartesian Growth Corporation III Unit
NASDAQ:CGCTU
|
USA | $281.56 Million |
|
Azure Holding Group Corp
PINK:AZRH
|
USA | $16.92 Million |
|
Constellation Capital Corp.
V:CNST-P
|
Canada | CA$627.53K |
|
Little Fish Acquisition I Corp.
V:LILL-P
|
Canada | CA$56.48K |
|
Hana 30 Special Purpose Acquisition Company
KQ:469880
|
Korea | ₩17.89 Billion |
|
Chicane Capital I Corp.
V:CCIC-P
|
Canada | CA$199.07K |
|
Cuspis Capital II Ltd
V:CCII-P
|
Canada | CA$1.51 Million |
Innovation1 Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Innovation1 Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Innovation1 Biotech Inc is currently not profitable relative to its asset base.
Innovation1 Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.06 | 0.05 |
| Quick Ratio | 0.04 | 0.06 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.79 Million | $ -2.19 Million | $ -2.39 Million |
Innovation1 Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Innovation1 Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -99.8% |
| Total Assets | $75.99K |
| Market Capitalization | $4.49K USD |
Valuation Analysis
Below Book Valuation: The market values Innovation1 Biotech Inc's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Innovation1 Biotech Inc's assets decreased by 99.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Innovation1 Biotech Inc (2018–2023)
The table below shows the annual total assets of Innovation1 Biotech Inc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-08-31 | $75.99K | -99.83% |
| 2022-08-31 | $43.96 Million | +24070.86% |
| 2021-08-31 | $181.89K | -12.81% |
| 2020-08-31 | $208.60K | -18.65% |
| 2019-08-31 | $256.41K | -70.28% |
| 2018-08-31 | $862.74K | -- |